Antengene Corporation Limited
德琪醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6996)

TGA IN AUSTRALIA APPROVES XPOVIO® (SELINEXOR) FOR RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA AND TRIPLE CLASS-REFRACTORY MULTIPLE MYELOMA

This announcement is made by Antengene Corporation Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group. The board of directors of the Company (the "**Board**") is pleased to announce that Australia's Therapeutic Goods Administration (TGA) has registered XPOVIO® (selinexor) for two indications: (1) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy and (2) in combination with dexamethasone for the treatment of adult patients with relapsed and/or refractory multiple myeloma (rrMM) who have received at least three prior therapies and whose disease is refractory to at least one proteasome inhibitor, at least one immunomodulatory medicinal product, and an anti-CD38 monoclonal antibody.

This is a voluntary announcement made by the Company. The Group cannot guarantee that XPOVIO® (selinexor) will ultimately be successfully marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Antengene Corporation Limited
Dr. Jay Mei
Chairman

Hong Kong, March 9, 2022

As at the date of this announcement, the board of directors of the Company comprises Dr. Jay Mei, Mr. John F. Chin, Dr. Kevin P. Lynch and Mr. Donald A. Lung as executive directors; Dr. Kan Chen and Mr. Yilun Liu as non-executive directors; and Mr. Mark J. Alles, Ms. Jing Qian and Mr. Sheng Tang as independent non-executive directors.

About the SINE Compounds

SINE (Selective Inhibitor of Nuclear Export) compounds are inhibitors of the major nuclear export protein Exportin 1 (XPO1). Currently, there are three oral SINE compounds, ATG-010 (Selinexor), ATG-016 (Eltanexor), and ATG-527 (Verdinexor), under clinical development. Antengene has an exclusive license from Karyopharm Therapeutics Inc. ("**Karyopharm**") for these compounds in certain Asia-Pacific markets.

ATG-010/Selinexor/XPOVIO®

Selinexor is the first and only oral XPO1 inhibitor approved by the U.S. Food and Drug Administration ("**FDA**"). By blocking the nuclear export protein XPO1, selinexor can promote the intranuclear accumulation and activation of tumor suppressor proteins and growth regulating proteins, and down-regulate the levels of multiple oncogenic proteins. Due to its novel mechanism of action, selinexor is being evaluated for use in multiple combination regimens to improve treatment outcome.

Selinexor is approved by the U.S. FDA for the treatment of relapsed/refractory multiple myeloma (rrMM) and relapsed/refractory diffuse large B-cell lymphoma (rrDLBCL).

Antengene secured approval of selinexor in China in December 2021 for rrMM and plans to launch the product in the second quarter of 2022. Antengene also secured approval for selinexor in South Korea for use in rrMM and rrDLBCL in July 2021, in Singapore for use in rrMM and rrDLBCL and in Australia for use in rrMM in March 2022. Antengene is conducting 10 studies in mainland China (3 in collaboration with Karyopharm) for relapsed/refractory hematological malignancies and advanced solid tumors.

About Antengene

Antengene Corporation Limited ("**Antengene**", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on innovative first-in-class/best-in-class therapeutic medicines for oncology and other life-threatening diseases. Driven by its vision of "Treating Patients Beyond Borders", Antengene aims to provide the most advanced anti-cancer drugs to patients in the Asia Pacific Region and around the world. Since initiating operations in 2017, Antengene has obtained 21 investigational new drug (IND) approvals in the U.S. and in Asia, submitted 6 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for ATG-010/Selinexor/XPOVIO® in China, South Korea, Singapore and Australia already approved. Leveraging partnerships as well as in-house drug discovery, Antengene has built a broad and expanding pipeline of 15 clinical and pre-clinical assets. The Company has global rights on 10 programs and Asia Pacific rights, including the Greater China region, on 5 programs.

Forward-Looking Statements

The forward-looking statements made in this announcement only to the events or information as of the date on which the statements are made in this announcement. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this announcement completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this announcement, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this announcement. Any of these intentions may alter in light of future development. Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to ultimately market ATG-010 (selinexor) successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.